Abstract: An encoder includes a rotor including: a shaft and a code disk attached to the shaft; a stator including a scanning unit configured to generate an electrical signal corresponding to an angular position of the code disk; a cable configured to transfer the electrical signal; and a cover overmolded onto the stator, where the scanning unit is sealed from an outer environment by the cover.

Abstract: An encoder device includes: an encoder base; a hub rotatably arranged in the encoder base and arranged to carry an encoder disk; and an alignment device arranged to urge the hub into a predetermined axial and radial position relative to a portion of the housing, the alignment device including a contact portion arranged to contact an axial surface of the encoder base, a locating structure arranged to maintain the alignment device in a predefined radial position, a flange structure arranged to contact an axial surface of the hub and a circumferential portion of the hub, and a spring structure arranged to urge the hub axially toward the flange element, where the alignment device urges the hub into a predetermined axial and radial position relative to a portion of the encoder base, and the spring structure contacts the hub so as to form a detent, the detent allowing the alignment device to be removed from the hub by pulling the alignment device axially away from the hub.

Abstract: An encoder includes a rotor including: a shaft and a code disk attached to the shaft; a stator including a scanning unit configured to generate an electrical signal corresponding to an angular position of the code disk; a cable configured to transfer the electrical signal; and a cover overmolded onto the stator, where the scanning unit is sealed from an outer environment by the cover.

Abstract: An encoder includes a base member and a cover attachable to the base member. The cover includes a surface with an opening and a strain relief device associated with the opening. The strain relief device includes at least one extension member extending from the surface of the cover and at least one bar member extending from the at least one extension member. The strain relief device is integral with the cover.

Abstract: An encoder includes a base member and a cover attachable to the base member. The cover includes a surface with an opening and a strain relief device associated with the opening. The strain relief device includes at least one extension member extending from the surface of the cover and at least one bar member extending from the at least one extension member. The strain relief device is integral with the cover.

Abstract: A method for delivering a naked or isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of a naked polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.

Abstract: A modular encoder includes an encoder housing and a printed circuit board mounted in the encoder housing. The modular encoder also includes a mounting bracket adapted to electrically couple to the printed circuit board and a mounting screw adapted to couple the encoder housing to a motor and to electrically couple the mounting bracket to the motor.

Abstract: A modular encoder includes an encoder housing and a printed circuit board mounted in the encoder housing. The modular encoder also includes a mounting bracket adapted to electrically couple to the printed circuit board and a mounting screw adapted to couple the encoder housing to a motor and to electrically couple the mounting bracket to the motor.

Abstract: The present invention features compositions and methods for inhibiting fertility or inducing contraception in a mammal. The compositions comprise a nucleic acid molecule, typically an immunostimulatory nucleic acid.

Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.

Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.

Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.

Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 6 to about 40 amino acid residues having a sequence corresponding to the sequence of a CMV-encoded polypeptide antigen. The diagnostic methods and systems are particularly useful in identifying infections mononucleosis during its acute phase.

Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.

Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.

Abstract: The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.

Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences--Gly--R.sup.1 --Gly--R.sup.2 --Gly-- (i)wherein R.sup.1 and R.sup.2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R.sup.1 and R.sup.2 are not both Gly; and--Gly--Ala--Gly--Gly--Ala--Gly--. (ii)The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma.

Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences(i) --Gly--R.sup.1 --Gly--R.sup.2 --Gly--wherein R.sup.1 and R.sup.2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R.sup.1 and R.sup.2 are not both Gly; and(ii) --Gly--Ala--Gly--Gly--Ala--Gly--.The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma.

Abstract: Antigens, immunogens, inocula, antibodies, diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. Each of the compounds, compositions, methods or systems contains a synthetic, random copolymer polypeptide having about 6 to about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the five amino acid residue sequence -Gly-R.sup.1 -Gly-R.sup.2 -Gly-, wherein R.sup.1 and R.sup.2 are the same or different amino acid residues selected from the group consisting of Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr, with the provision that R.sup.1 and R.sup.2 are not both Gly. The polypeptide contains at least 25 mole percent Gly residues, and when linked to a carrier and introduced in an effective amount into a mammalian host is capable of inducing production of antibodies that immunoreact with EBNA.

Abstract: Antigens, immunogens, inocula, antibodies, diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. Each of the compounds, compositions, methods or systems contains a synthetic, random copolymer polypeptide having about 6 to about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the five amino acid residue sequence -Gly-R.sup.1 -Gly-R.sup.2 -Gly-, wherein R.sup.1 and R.sup.2 are the same or different amino acid residues selected from the group consisting of Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr, with the provision that R.sup.1 and R.sup.2 are not both Gly. The polypeptide contains at least 25 mole percent Gly residues, and when linked to a carrier and introduced in an effective amount into a mammalian host is capable of inducing production of antibodies that immunoreact with EBNA.